Trials / Terminated
TerminatedNCT03861728
Viral Conjunctivitis Treatment Study
Avenova for the Treatment of Viral Conjunctivitis
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | 0.01% Hypochlorous acid | Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device) |
| OTHER | Placebo | Placebo to be used four times a day to the affected eye for 2 weeks |
Timeline
- Start date
- 2018-11-14
- Primary completion
- 2020-02-08
- Completion
- 2020-02-08
- First posted
- 2019-03-04
- Last updated
- 2021-12-29
- Results posted
- 2021-12-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03861728. Inclusion in this directory is not an endorsement.